Higher-Dose Rifampin

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tuberculosis

Conditions

Tuberculosis

Trial Timeline

Sep 1, 2013 → Apr 1, 2016

About Higher-Dose Rifampin

Higher-Dose Rifampin is a phase 2 stage product being developed by Sanofi for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01408914. Target conditions include Tuberculosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01408914Phase 2Completed

Competing Products

20 competing products in Tuberculosis

See all competitors